 |
|
|
| |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in
Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years:
Pooled Results From the TANGO and SALSA Studies
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Sharon Walmsley,1 Don E. Smith,2 Miguel Górgolas,3 Pedro E. Cahn,4 Thomas Lutz,5 Karine Lacombe,6 Princy N. Kumar,7 Brian Wynne,8 Richard Grove,9
Gilda Bontempo,8 Riya Moodley,10 Frank Spinelli,8 Bryn Jones,10 Chinyere Okoli,10 Mounir Ait-Khaled10
1University Health Network, Toronto, ON, Canada; 2Albion Centre, Sydney, Australia; 3Fundación Jimenez Díaz, Universidad Autónoma de Madrid, Madrid, Spain; 4Fundación Huesped, Buenos Aires,
Argentina; 5Infektiologikum, Frankfurt, Germany; 6Hopital Saint-Antoine, Paris, France; 7Georgetown University Medical Center, Washington, DC, USA; 8ViiV Healthcare, Durham, NC, USA;
9GSK, Brentford, UK; 10ViiV Healthcare, Brentford
|
| |
|
|
|
|
|
